Result Summary for ROF102100
| Protocol ID: | ROF102100 |
| Clinical Study ID: | ROF102100 |
| Official Title: | A randomised, double blind, placebo-controlled, parallel group study to investigate the safety and efficacy of controlled-release ropinirole (CR) (1-24 mg) administered once daily for 12 weeks in subjects with fibromyalgia |
| Phase: | Phase 2 |
| Study Indications or Diseases: |
|
| Generic Name: | ropinirole |
| Trade/Product Name: | Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara |
| Approved Drug Label: | http://www.gsk.com/products.html |
| Results Summary: |  Click
here to download result summary. |
| Citations: |
|
The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.
